Biomarin Pharmaceutical Inc
BMRN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$74.00 | Rhqqlf | Qzcmybyf |
BioMarin Earnings: Voxzogo’s Success Counters Roctavian Headwinds
BioMarin’s first-quarter revenue grew 15% to nearly $600 million, and we think this puts the firm in a good position to meet our forecast of roughly $2.4 billion for the full year, factoring in continued Kuvan generic headwinds, but also strong uptake of new achondroplasia drug Voxzogo. We’re maintaining our $96 fair value estimate.